Objectives: The emergence of antibiotic resistance has seriously diminished antibiotic efficacy and an increasing number of infections are becoming difficult to treat. One approach to the restoration of antibiotic activity is to administer them in conjunction with non-antibiotic compounds that depress resistance mechanisms. We describe the activity of ellagic and tannic acids as adjuvants that enhance the activity of aminocoumarin antibiotics against multidrug-resistant (MDR) Acinetobacter baumannii.
Introduction
Acinetobacter spp. are ubiquitous, non-lactose-fermenting Gram-negative coccobacilli that have emerged in recent years as major causes of nosocomial infections associated with significant morbidity and mortality rates.
1,2 Acinetobacter baumannii 3 is most commonly involved, resulting in a wide spectrum of infections, including pneumonia, bacteraemia, urinary tract infection, and skin and soft tissue infections. 4 -6 Acinetobacter infections are difficult to treat, due to both the pathogen's intrinsic resistance and its ability to readily acquire new resistance mechanisms. 7 -10 It has been suggested that we are closer to the end of the antibiotic era with Acinetobacter than with methicillin-resistant Staphylococcus aureus. 4, 11 Many epidemic
Acinetobacter strains are resistant to most available antibiotics, but one exception is colistin; 12 -14 unfortunately, this antibiotic causes nephrotoxicity, neuromuscular blockage and neurotoxicity. 15 There is a pressing need for new therapeutic options in the treatment of severe infections caused by multidrug-resistant (MDR) A. baumannii.
DNA gyrase and DNA topoisomerase IV are targets for several antibacterial drugs. One of the main classes of antibiotics that target these key enzymes are the aminocoumarins that bind to the B subunit of bacterial DNA gyrase, inhibiting the ATP hydrolysis required for ATP-dependent DNA supercoiling. 16 Novobiocin (Albamycin) is the only aminocoumarin that has been licensed for the treatment of human infections by Gram-positive bacteria; however, its low level of activity against Gram-negative pathogens is a major limitation. The effectiveness of the aminocoumarins against Gram-negative bacteria is limited by the uptake of these antibiotics across the bacterial outer membrane. 17, 18 The resistance of A. baumannii to novobiocin is further facilitated by drug efflux involving the AdeIJK efflux pumps. 7 Inactivating these efflux pumps restore the susceptibility to novobiocin and other antibiotics.
The study of natural products from plants has certain advantages: they can be sourced easily and selected on the basis of their ethnomedicinal use. 19, 20 There is significant interest in plant compounds that inhibit bacterial efflux pumps, such as the plant alkaloid reserpine, which is an efflux pump inhibitor (EPI) for NorA 21, 22 and TetK. 23 Unfortunately, the concentrations of this compound required for inhibition cause toxic reactions in humans. 24 According to recent reviews, 25, 26 no natural EPI effective for use with A. baumannii is available; therefore, there is a clinical need for antibiotic adjuvants with EPI activity.
Plant-derived phenolic compounds display a variety of biological activities and are readily available from common dietary sources. We have tested the antibiotic adjuvant activity of some plant phenolics against MDR A. baumannii using novobiocin as a model antibiotic.
Materials and methods

Plant-derived compounds, chemicals and media
Plant-derived compounds, including catechol, cinnamic acid, p-coumaric acid, ellagic acid, ferulic acid, gallic acid, quercetin, tannic acid and syringic acid, were purchased from Sigma -Aldrich (St Louis, MO, USA). Ellagitannin was kindly provided by Dr B. E. Yingyongnarongkul (Ramkhamhaeng University, Bangkok, Thailand). All test compounds were dissolved in DMSO (Fisher Scientific, Fair Lawn, NJ, USA) to a concentration of 10 mM. In all experiments, 1% DMSO was used as control.
Mueller -Hinton broth (MHB) and agar (MHA) were from Becton Dickinson Microbiology Systems (Sparks, MD, USA). Carbonyl cyanide m-chlorophenylhydrazone (CCCP), reserpine, ethidium bromide (EtBr), 1-N-phenylnaphthylamine (NPN) and pyronin Y were obtained from Sigma -Aldrich, and EDTA was obtained from Fisher Scientific (Fair Lawn, NJ, USA).
Bacterial strains and antibacterial assay
Clinical isolate MDR A. baumannii JVC1053 was kindly provided by Dr. D. Roscoe (Vancouver General Hospital, BC, Canada). This strain is resistant to levofloxacin, aztreonam, ciprofloxacin and trimethoprim/sulfamethoxazole, but is susceptible to amikacin and ceftazidime. A. baumannii ATCC 19606 was included in this study as an antibiotic-susceptible, non-MDR reference strain. The MIC was determined by serial dilution of test compounds in MHB with bacteria at a density of 5Â10 5 cfu/mL. 27 Plates were incubated at 378C for 18 h and then growth was assayed with a microtitre plate reader (Wallac 1420 Victor Multilabel counter, Perkin-Elmer, Turku, Finland), by monitoring the optical density (OD) at 595 nm.
Primary screening for antibiotic adjuvants
The bacterial culture was inoculated at 10 6 cfu/mL into a 96-well microtitre plate containing novobiocin at a concentration of Effect of antibiotic adjuvants on antibiotic susceptibility patterns of A. baumannii
The susceptibility of bacterial cultures to a panel of selected antibiotics, including aminoglycosides (neomycin, amikacin, tobramycin and gentamicin), b-lactams (ampicillin and imipenem), fusidic acid, macrolides (erythromycin and azithromycin), rifampicin, tetracycline and aminocoumarins, was conducted on MHA with or without 40 mM ellagic and tannic acid supplementation. Antibiotic susceptibility test discs were purchased from Becton Dickinson Microbiology Systems (Sparks, MD, USA), Difco (Detroit, MI, USA) or made using the laboratory collection of antibiotics. Susceptibility was determined on MHA supplemented with the EPIs CCCP and reserpine, and with the permeabilizer, EDTA. The diameters of inhibition zones were measured after incubation of the plates at 378C for 18 h and compared with the inhibition zones on MHA alone.
Adjuvant activity of ellagic and tannic acids with antibiotics
MIC values and growth inhibition assays of aminocoumarins (novobiocin, chlorobiocin and coumermycin), fusidic acid, rifampicin and tetracycline in the presence of ellagic or tannic acids were established in MHB in the presence of 10-40 mM ellagic and tannic acids by broth microdilution; six concentrations of each antibiotic, ranging from 1ÂMIC to 1 32 ÂMIC, were tested. Adjuvant (50 mL) was added to 50 mL of various concentrations of the test antibiotics. Bacterial suspensions at an OD 600 of 0.4 corresponding to 10 8 cfu/mL were diluted and a final inoculum of 10 6 cfu/mL in MHB (100 mL) was then added into microtitre plates. The plates were incubated for 18 h at 378C and then growth was observed using a microtitre plate reader. Growth studies were performed as described above. Samples were taken every hour for 8 h.
Permeabilization of the outer membrane
NPN fluorescence is associated with the presence of this hydrophobic probe in a glycerophospholipid environment, such as the lipid bilayers of biological membranes; increased fluorescence values indicate weakening of the outer membrane. NPN uptake by bacterial suspensions was measured using black microtitre plates (BD Biosciences-Labware, Franklin, NJ, USA) in a Wallac 1420 Victor Multilabel counter (excitation, 355 nm; emission, 460 nm). 28 The bacterial cultures (OD 600 $ 0.5) were collected by centrifugation at 3500 rpm for 10 min and resuspended in an equal volume of 5 mM HEPES buffer ( pH 7.2). Aliquots (100 mL) of this cell suspension were added to the microtitre plate, containing 50 mL of ellagic acid (40 mM), tannic acid (40 mM), EDTA (1 and 0.25 mM) or HEPES buffer (control). NPN (40 mM) was then added immediately to a total volume of 200 mL. Fluorescence was monitored within 3 min and continuously recorded every 10 min for 3 h. Each assay was performed at least three times.
EtBr and pyronin Y efflux
The inhibition of bacterial efflux pumps was established by measurement of the level of EtBr and pyronin Y accumulation using the method described previously. 29, 30 Overnight cultures of A. baumannii JVC1053 were diluted in PBSþ 0.4% glucose (pH 7.4) and incubated to an OD 600 of 0.5. The suspension was transferred to a 96-well plate and pre-treated with ellagic acid, CCCP or 1% DMSO for 5 h. EtBr was added to a final concentration of 4 mg/L and the relative fluorescence intensity was measured in a Safire (Tecan, Crailsheim, Germany) fluorescence plate reader (excitation, 518 nm; emission, 605 nm). A similar assay was performed with pyronin Y (excitation, 545 nm; emission, 570 nm).
Results
Antibacterial activity and antibiotic adjuvant ability of the plant polyphenols
The plant-derived compounds to be used exhibited no intrinsic antibacterial activity against A. baumannii JVC1053 (MIC ! 320 mM). This strain exhibited a novobiocin MIC of 32 mg/L.
Tests of the plant compounds for their antibiotic adjuvant ability in combination with a subinhibitory concentration of novobiocin against MDR A. baumannii are shown in Table 1 . With the exception of ellagitannin and tannic acids, the plant polyphenols displayed weak effects on bacterial growth at 40 mM. Ellagic and tannic acids completely inhibited bacterial growth in the presence of Antibiotic susceptibility patterns of A. baumannii in the presence of antibiotic adjuvants Table 2 shows the ellagic and tannic acid enhancement of the antibacterial activity of aminocoumarins, rifampicin, fusidic acid and tetracycline against A. baumannii. Ellagic acid supplementation did not increase the susceptibility of MDR A. baumannii to macrolides, aminoglycosides, ampicillin and colistin, but did improve the antibacterial activity of macrolides and aminoglycosides against the ATCC 19606 strain. The activity of imipenem was slightly reduced. The changes in the susceptibility patterns of the A. baumannii strains in the presence of ellagic and tannic acids were compared with those of known antibiotic adjuvants, including EDTA, CCCP and reserpine. Different concentrations of ellagic and tannic acids (10 -40 mM) were further tested for their stimulation of antibacterial activities of aminocoumarins, rifampicin, fusidic acid and tetracycline against both MDR and reference A. baumannii strains (Table 3 ). In the presence of all concentrations of ellagic acid, the MICs of the test antibiotics, with the exception of tetracycline, were reduced 2-to 4-fold. Tannic acid stimulated the antibacterial activities against MDR A. baumannii (the MIC values were changed 2-to 4-fold), but did not decrease the MIC of fusidic acid against the MDR strain.
Combinations of ellagic acid (10 mM or 3 mg/L) with novobiocin, chlorobiocin, coumermycin, fusidic acid or rifampicin (1/8 to 1/16 of the antibiotic only MIC) dramatically reduced the bacterial growth in both the MDR and the reference strains ( Figure 1) . Furthermore, growth studies, as presented in Figure 2 , confirmed these results.
Effect of ellagic and tannic acids on the membrane permeability and active efflux pumps of A. baumannii
Results of NPN uptake experiments with the permeabilizer EDTA (1 and 0.25 mM) and the antibiotic adjuvants ellagic and tannic acids (40 mM) are presented in Figure 3 . EDTA weakened the outer membrane of both clinically isolated A. baumannii and the reference strain, as indicated by an increase in the NPN uptake. Neither ellagic nor tannic acids enhanced NPN uptake. Figure 4 illustrates the effect of ellagic acid on cell accumulation of EtBr and pyronin Y. In the presence of different concentrations of ellagic acid, ranging from 3 to 24 mg/mL, the accumulation of pyronin Y was dramatically increased, while no enhancement of the accumulation of EtBr was observed.
Discussion
We have shown that certain plant phenolic compounds enhance the activity of a variety of antibiotics against MDR A. baumannii. In particular, ellagic acid at 40 mM (12 mg/L), which has no intrinsic antibacterial activity, in combination with Enhancing the anti-Acinetobacter activity of novobiocin Enhancing the anti-Acinetobacter activity of novobiocin the GyrA inhibitor novobiocin led to a marked decrease in the bacterial growth. The antibiotic adjuvant abilities of this compound (changes in antibacterial susceptibility patterns of A. baumannii strains in the presence of ellagic acid) were compared with those in the presence of the permeabilizer EDTA, and the EPIs CCCP and reserpine. Although the antibiotic adjuvant ability of the plant phenolic compound was similar to that of the permeabilizer EDTA, in contrast to other permeabilizers 31 neither ellagic nor tannic acids increased the bacterial uptake of NPN. This is similar to results found in Salmonella enterica serovar Typhimurium. 28 Intrinsic and acquired multidrug resistance in Gram-negative bacteria is related to the synergistic interaction between limited outer membrane permeability and energy-dependent multidrug efflux pumps. 32 Enhancement of novobiocin activity against other Gram-negative bacteria, such as Pseudomonas aeruginosa Chlorobiocin ( × MIC) + ellagic acid (20 µM) 1 4 Chlorobiocin ( × MIC) + ellagic acid (10 µM) 1 4 Chlorobiocin ( × MIC) 1 4 Novobiocin ( × MIC) + ellagic acid (40 µM) 1 4 Novobiocin ( × MIC) + ellagic acid (20 µM) 1 4 Novobiocin ( × MIC) + ellagic acid (10 µM) 1 4 Novobiocin ( × MIC) 1 4 1% DMSO Ellagic acid (10 µM) Ellagic acid (20 µM)
Ellagic acid (40 µM) Coumermycin ( × MIC) + ellagic acid (40 µM) 1 4 Coumermycin ( × MIC) + ellagic acid (20 µM) 1 4 Coumermycin ( × MIC) + ellagic acid (10 µM) 1 4 Coumermycin ( × MIC) 1 4 1% DMSO Ellagic acid (10 µM) Ellagic acid (20 µM) Ellagic acid (40 µM) Rifampicin ( × MIC) + ellagic acid (40 µM) 1 4 Rifampicin ( × MIC) + ellagic acid (20 µM) 1 4 Rifampicin ( × MIC) + ellagic acid (10 µM) 1 4 Rifampicin ( × MIC) 1 4 Fusidic acid ( × MIC) + ellagic acid (20 µM) 1 8 Fusidic acid ( × MIC) + ellagic acid (10 µM) and Stenotrophomonas morelense by EDTA and polyethyleneimine, compounds that alter outer membrane permeability, has been reported. 33, 34 Similar activity was found for berry-derived phenolic compounds, including 3,4-dihydroxyphenylacetic acid, 3-hydroxyphenylacetic acid and 3-(3,4-dihydroxyphenyl) propionic acid. 35 Such compounds efficiently destabilize outer Enhancing the anti-Acinetobacter activity of novobiocin membrane permeability and increased the novobiocin susceptibility of S. enterica Typhimurium. Although ellagic acid exhibited a synergistic effect with novobiocin as well as other aminocoumarins, the mechanisms may not be similar to those reported for other known permeabilizers. Broad-range efflux systems are universal in microorganisms and confer resistance to many compounds, including antibiotics, by drug extrusion. To date, three resistance -nodulation -cell division (RND) efflux systems, including AdeABC, 9 AdeDE 36 and AdeIJK, 7 have been described in Acinetobacter. Novobiocin, fusidic acid, rifampicin and pyronin Y were exported by the AdeIJK efflux pump, while EtBr is a substrate for AdeABC. An EPI, 1-(1-naphthylmethyl)-piperazine (NMP), was found to moderately reverse multidrug resistance in both an Escherichia coli overexpressing an RND type efflux pump 37 and clinical isolates. 29 Furthermore, NMP has been shown to partially reverse MDR in A. baumannii, but was not capable of destabilizing the outer membrane of the tested bacteria. 38 Ellagic acid is a dimeric derivative of gallic acid, which naturally exists in fruits and nuts such as raspberry, cloudberry, strawberry, grapes, pomegranates and chestnuts. 39 -41 It is usually found in combination with its precursor, hexahydroxydiphenic acid, or bound to glucose in the form of ellagitannins. 39 Interest in ellagic acid has increased during the past few years due to its potential antimutagenic and anticarcinogenic effects. 42 Several different mechanisms of action have been suggested for ellagic acid activity, some of which involve binding to protein or DNA. 43 Ellagic acid is an approved food additive in Japan, functioning as an antioxidant, and its levels of toxicity have been established. 44 In conclusion, ellagic acid improves the antibacterial activity of aminocoumarins, rifampicin and fusidic acid against the serious Gram-negative pathogen A. baumannii. Ellagic acid represents a promising antibiotic adjuvant lead compound, especially given its low cytotoxicity. 
